Search

Precision, accuracy, and temporal resolution are key to making full use of atmospheric trace gas records in ice cores. These aspects will become especially crucial for ice cores that aim to extend the ice core record to the last 1.5 Myr, i.e., across the Mid-Pleistocene Transition (as currently drilled within the European project Beyond EPICA – Oldest Ice Core (BE-OIC)). The ice from this period is expected to be close to bedrock and, due to glacier flow, extremely thinned with 15 000 years of climate history contained in only 1 m of ice. Accordingly, for a century-scale resolution, the sample vertical extent must be reduced to a few centimeters containing only about 1–2 mL air STP. We present a novel combined system for the extraction and the simultaneous measurement of CO2, CH4, and N2O concentrations, as well as δ13CO2, which achieves a vertical resolution of 1–2 cm (3.5×3.5 cm cross section) with precisions of 0.4 ppm, 3 ppb, 1 ppb, and 0.04 ‰, respectively, in sublimation tests with standard gas over gas-free ice. This is accomplished by employing a directional and continuous laser-induced sublimation followed by analysis of the sample gas by a quantum cascade laser absorption spectrometer (QCLAS). Besides the low sample volume requirements and the vertical resolution capabilities, the described method holds additional advantages over previous methods, including the immunity of the highly specific QCLAS analysis to drilling fluid contamination as well as the non-destructive nature of the spectroscopic gas analysis. The combined extraction and analysis system was extensively tested by sublimating gas-free ice with introduction of a standard gas to determine the accuracy and characterize potential artifacts. Moreover, Antarctic ice samples were measured to confirm the measurement performance, covering the range of variability expected in Pleistocene ice and highlighting the vertical resolution capabilities critical for its application within BE-OIC.

e15524 Background: Biomarker discovery and development are essential for stratifying cancer patients in order to improve treatment outcomes. In colorectal cancer (CRC), mutations in the TGF-β/BMP pathway, especially in the SMAD4 gene have been correlated with decreased overall survival and are suspected to modulate drug sensitivity on the cellular level, hence SMAD4 mutations are worthwile targets for novel targeted therapy aproaches. Methods: In the present study, we uncover the mechanistic role of a loss-of-function mutation in SMAD4 in syngeneic patient-derived organoids (PDOs). CRISPR-engineered SMAD4R361H PDOs were subjected to a comparative drug screening, RNA-Sequencing and multiplex protein profiling analysis (DigiWest®). We have confirmed the response towards MEK inhibition of the initial model in an additional set of 62 PDOs with known mutational status. Results: We show that acquisition of SMAD4 loss-of-function mutations renders PDOs sensitive to MEK-inhibitors. Further, an activation of the TGF-β/BMP signaling pathway, specifically of the BMP branch was observed in SMAD4wt PDOs; indicating that BMP signaling is likely responsible for the resistance towards MEK inhibition. It is plausible that functional loss of SMAD4 and thus loss of BMP signaling renders SMAD4 mutated tumors more sensitive to MEK-inhibitors. By looking at additional genes involved in TGF-β/BMP signaling that are frequently mutated in CRC, we identified the novel gene mutational SFAB-signature ( SMAD4, FBXW7, ARID1A, or BMPR2), when at least one pathogenic mutation is present in these genes. The frequency of SFAB in CRC patient cohort (TCGA, n = 594) was comparable to the frequency of SFAB in our PDOs. For PDOs with SFAB-signature, we found up to 95% and 70% significant positive prediction for cobimetinib and selumetinib, respectively and also up to 70% positive prediction for trametinib. Thus, the SFAB-signature predicts response to MEK inhibition in PDOs with a very high confidence. We further investigated whether the RAS status of CRC PDOs does predict sensitivity to MEK inhibition. The RAS status alone and in combination with SFAB-signature failed to yield better prediction sensitivity to MEK-inhibitors. Conclusions: The present study is a significant step forward to more personalized treatment regimens for CRC patients by early inclusion of MEK-inhibitors. The SFAB-signature should be put to clinical testing as a RAS-independent biomarker for stratification of patients providing a valuable alternative treatment option against CRC, thus ensuring that all patients receive effective and specific therapies as early as possible.

Trauerschrift auf Curt Reinicke Graf von Calenberg, +20. April 1709